Reported results
- Cash and cash equivalents totaled $29.7 million as of September 30, 2026, compared to $4.3 million as of December 31, 2025.
- Funding under federal grants was $2.2 million for the third quarter of 2026 compared to $0.5 million for the third quarter of 2025.
- Research & development expenses were $3.2 million for the third quarter of 2026 compared to $3.0 million for the third quarter of 2025.
- General & administrative expenses were $1.6 million for the third quarter of 2026 compared to $1.3 million for the third quarter of 2025.
- Acquired in-process research and development charge was approximately $79.9 million for the third quarter of 2026.
- Net loss attributable to common stockholders for the third quarter of 2026 was $82.3 million, or $(4.52) per basic and diluted share, compared to $3.7 million, or $(1.29) per basic and diluted share, for the third quarter of 2025.
Notes
Net loss attributable to common stockholders for the third quarter of 2026 includes a non-cash acquired IPR&D charge of approximately $79.9 million related to the acquisition of Cy Biopharma and a $0.2 million deemed dividend related to the retirement of the Series B Preferred Stock.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
